Bayer Reports Improvement in Clinical Plan for Riociguat Based on positive Stage II trial findings.

Bayer Reports Improvement in Clinical Plan for Riociguat Based on positive Stage II trial findings, Bayer Schering Pharma will transfer to Phase III trials using its oral agent riociguat http://silagra-rx.com . Riociguat may be the 1st member of a fresh class of vasodilating brokers known as soluble guanylate cyclase stimulators. It really is getting investigated as a fresh approach for the treating different types of pulmonary hypertension. Riociguat demonstrated considerably improved exercise capability in a Stage II study in sufferers with chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension when compared with baseline values.

Other entries from category "physiotherapy":

Random entries